it’s important to note that the Race team and world class cardio-oncologists have have ok’d the CPACS combo. They have access to the data, we don’t! yet still they are confident enough for a P2 and constant buying on market by DrT.
Next step RC220 release this month then straight into clinical validation. Its not just a safety trial it’s proof of concept in a basket trial and a new drug class. Triple validation, cardio protect, FTO and multiple cancer synergy.
Is the science works where does this fit in commercially? Well my view is DACS-F (Decitabine Anti-Cancer Synergy+FTO) is being severely underestimated. If DACS-F really flips a liquid tumour only therapy to solid tumour multi-indication who else would want this in the hands of their competitors.
Expect traction on DACS-F to progress in the next 12 months, if Astex liked AML what will they think on DACS-F?
Watch this space - best of luck!
- Forums
- ASX - By Stock
- Cardioprotection thread
it’s important to note that the Race team and world class...
-
- There are more pages in this discussion • 341 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $281.1M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1678 | $1.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.61 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 508 | 1.650 |
1 | 22586 | 1.645 |
1 | 17732 | 1.630 |
1 | 1279 | 1.555 |
1 | 25000 | 1.550 |
Price($) | Vol. | No. |
---|---|---|
1.610 | 100 | 1 |
1.620 | 1500 | 1 |
1.650 | 99 | 1 |
1.700 | 6610 | 4 |
1.745 | 12136 | 1 |
Last trade - 09.59am 29/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
Day chart unavailable
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online